Commentary: Tackling corruption in the life sciences sector
21 July 2009
Amy J Conway-Hatcher, Jurgen Beninca & Emma O'Kane
What is the risk that business practices in life science companies might be found to be corrupt by enforcement agencies? Amy J Conway-Hatcher, Jürgen Beninca and Emma O’Kane of the US-based law firm Morgan Lewis describe some of the potential pitfalls for pharmaceutical executives.
Life...
Please Login to read the full article.
21 July 2009
Amy J Conway-Hatcher, Jurgen Beninca & Emma O'Kane
Life...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Industry and EC seek public-private route to new antimicrobials
- FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines
- US Capitol Capsule: US drug shortages worsen, putting patients increasingly at risk
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
